公开(公告)号：US20160008391A1

公开(公告)日：2016-01-14

申请号：US14760604

申请日：2014-01-14

Applicant: INSTITUT PASTEUR ,  UNIVERSITÀ DEGLI STUDI DI PERUGIA ,  STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Jean-Paul LATGE ,  Thierry Vincent Gérard FONTAINE ,  Frank Leo VAN DE VEERDONK ,  Mark Sebastiaan GRESNIGT ,  Mihai NETEA ,  Leo AB JOOSTEN ,  Luigina ROMANI ,  Silvia BOZZA ,  Antonella DE LUCA

IPC: A61K31/715 ,  A61K45/06

CPC classification number: A61K31/715 ,  A61K31/726 ,  A61K45/06

Abstract: A first object of the invention is galactosaminogalactan comprising α1-4 linked galactose, α1-4 linked N-acetylgalactosamine, and optionally α1-4 linked galactosamine, for use in the treatment of at least one inflammatory disease. Another object of the invention is a pharmaceutical composition comprising a galactosaminogalactan comprising α1-4 linked galactose, α1-4 linked N-acetylgalactosamine, and optionally α1-4 linked galactosamine, as defined herein, and optionally a pharmaceutically acceptable carrier. Another object of the invention is a pharmaceutical composition according to the invention, for use in the treatment of at least one inflammatory disease. Another object of the invention is an inhibitor of IL-1RA for use in the treatment of human fungal diseases. Another object of the invention is a pharmaceutical composition comprising an inhibitor of IL-1RA, and optionally a pharmaceutically acceptable carrier.

Abstract translation: 本发明的第一个目的是包含α1-4连接的半乳​​糖，α1-4连接的N-乙酰半乳糖胺和任选α1-4连接的半乳​​糖胺的半乳糖胺半乳聚糖，用于治疗至少一种炎性疾病。 本发明的另一个目的是一种药物组合物，其包含含有α1-4连接的半乳​​糖，α1-4连接的N-乙酰半乳糖胺和任选地α1-4连接的半乳​​糖胺，如本文所定义的任选的药物可接受载体的半乳糖胺半乳聚糖。 本发明的另一个目的是根据本发明的药物组合物，用于治疗至少一种炎性疾病。 本发明的另一个目的是用于治疗人类真菌疾病的IL-1RA抑制剂。 本发明的另一个目的是一种药物组合物，其包含IL-1RA的抑制剂和任选的药学上可接受的载体。

公开(公告)号：US20130287794A1

公开(公告)日：2013-10-31

申请号：US13928557

申请日：2013-06-27

Applicant: Stichting Katholieke Universiteit

Inventor： Timothy R. D. J. Radstake

IPC: A61K39/395

CPC classification number: A61M1/3618 ,  A61K38/17 ,  A61K39/39541 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/24 ,  C07K16/2851 ,  C07K2317/76

Abstract: The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular, fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention, therefore, relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced.

Abstract translation: 本发明涉及分子免疫学领域，特别是在预防或治疗自身免疫性疾病领域，特别是系统性硬化症或硬皮病领域。 本发明是基于SSC患者血浆CXCL4水平升高的观察。 这被发现有助于SSc的发病机制，特别是纤维化。 当CXCL4在体外实验中被中和时，可以中和纤维化作用。 这导致我们得出结论，通过降低CXCL4的血浆水平可以治愈SSc。 因此，本发明涉及用于治疗或预防硬皮病患者纤维化的方法，其中CXCL4的血浆水平降低。

公开(公告)号：US12179603B2

公开(公告)日：2024-12-31

申请号：US17415520

申请日：2019-11-25

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Nigel Edward Hussey

IPC: B60L13/10 ,  B60L13/06 ,  B61B13/08 ,  H02N15/00 ,  H01F7/20

Abstract: The present invention is in the field of a National Individual Floating Transportation Infrastructure (NIfTI) wherein floating vehicles can travel by magnetic levitation and propagation. The vehicles can travel at a controllable height above the existing, albeit modified, road infrastructure and at relatively high speeds.

公开(公告)号：US12054716B2

公开(公告)日：2024-08-06

申请号：US17552372

申请日：2021-12-16

Applicant: Stichting Katholieke Universiteit

Inventor： Robert Wilhelmus Johanna Collin ,  Alejandro Garanto Iglesias ,  Franciscus Peter Maria Cremers ,  Silvia Albert

IPC: C07H21/04 ,  A61K9/00 ,  C12N15/113

CPC classification number: C12N15/113 ,  A61K9/0048 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/346 ,  C12N2320/32 ,  C12N2320/33

Abstract: The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease.

公开(公告)号：US11840705B2

公开(公告)日：2023-12-12

申请号：US16607824

申请日：2018-04-23

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Paul Kouwer ,  Alan Rowan ,  Maarten Jaspers ,  Paula De Almeida

IPC: C12N5/18 ,  C12N5/00 ,  C09D133/26 ,  C08J3/24 ,  C08F120/54

CPC classification number: C12N5/0018 ,  C08F120/54 ,  C08J3/246 ,  C09D133/26 ,  C08J2333/02 ,  C08J2333/26 ,  C08J2477/04 ,  C12N2533/40 ,  C12N2533/54

Abstract: A double network hydrogel including a polymer (A) having a persistence length between 10 and 1000 nm; a flexible polymer (B), wherein the persistence length is measured according to single molecule force microscopy measurement, wherein polymer (B) has an extended coil conformation at a first condition and a collapsed globular conformation at a second condition. Polymer (A) preferably is a polyisocyanate, while polymer (B) is a crosslinked flexible polymer like for example PNIPAM. A method for making a double network hydrogel.

公开(公告)号：US20220127674A1

公开(公告)日：2022-04-28

申请号：US17082489

申请日：2020-10-28

Applicant: Stichting Katholieke Universiteit

Inventor： Wilhelmus Theodorus Stefanus HUCK ,  Kinga MATULA ,  Francesca Maria RIVELLO

IPC: C12Q1/6886 ,  C12Q1/6818 ,  B01L3/00 ,  G01N33/533

Abstract: Novel methods for detecting circulating stromal cells are provided. The methods comprise the steps of incubating a sample, and comparing the pH and/or concentration of at least one molecule selected from the group consisting of lactic acid, lactate ions, and pyruvate ions, determined for the incubated volume to the pH and/or concentration of said at least one molecule, within said sample, wherein a decrease in pH and/or an increase in concentration of said at least one molecule, indicates said at least one circulating stromal cell is present in said sample.

公开(公告)号：US20220017572A1

公开(公告)日：2022-01-20

申请号：US17374437

申请日：2021-07-13

Applicant: Erasmus University Medical Center Rotterdam ,  Stichting Katholieke Universiteit

Inventor： Bob Johan SCHOLTE ,  Martinus Christiaan FEITERS ,  Mark DAMEN

IPC: C07K5/103 ,  C07K5/083 ,  A61P31/14 ,  A61K38/08 ,  C07K5/09 ,  C07K7/06 ,  C07K5/072 ,  C07K7/08 ,  A61K38/05 ,  C07K5/113 ,  A61K38/07 ,  A61K38/00

Abstract: Disclosed are geminoid peptide-like compound according to Formula I: R1—C(═O)—Zn—NR3-R2  (I) in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1 has a number of C atoms of 11 or more, preferably 11 to 19, and R2 has a number of C atoms of 12 or more, preferably 12 to 20; R3 is hydrogen or C1-C6 alkyl; n is an integer from 1-15; each Z independently is an amino acid residue, wherein Zn comprises an N-terminus attached to C(═O) and a C-terminus that is attached to NR3, for use as a medicament.

公开(公告)号：US20190255141A1

公开(公告)日：2019-08-22

申请号：US16310343

申请日：2017-06-16

Applicant: Erasmus University Medical Center Rotterdam ,  Stichting Katholieke Universiteit

Inventor： Bob Johan SCHOLTE ,  Martinus Christiaan FEITERS ,  Mark DAMEN

IPC: A61K38/08 ,  C07K7/06 ,  A61K38/07 ,  A61K38/05 ,  C07K5/072 ,  C07K7/08 ,  C07K5/083 ,  C07K5/09 ,  C07K5/103 ,  C07K5/113 ,  A61P31/14

Abstract: Disclosed are geminoid peptide-like compound according to Formula (I): R1—C(=0)-Zn—NR3—R2 in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1 has a number of C atoms of 11 or more, preferably 11 to 19, and R2 has a number of C atoms of 12 or more, preferably 12 to 20; R3 is hydrogen or C1-C-6 alkyl; n is an integer from 1-15; each Z independently is an amino acid residue, wherein Zn comprises an N-terminus attached to C(=0) and a C-terminus that is attached to NR3, for use as a medicament.

公开(公告)号：US10314508B2

公开(公告)日：2019-06-11

申请号：US15328083

申请日：2015-07-20

Applicant: Stichting Katholieke Universiteit

Inventor： Petrus Wilhelmus Maria Desain ,  Jordy Thielen ,  Philip Leonardus Cornelis van den Broek ,  Jason David Robert Farquhar

IPC: A61B5/0484 ,  G06F3/01 ,  A61B5/048 ,  A61B5/00 ,  A61B5/04 ,  A61B5/055

Abstract: Method for processing a brain wave signal (4) obtained from a person using a brain wave detector (5). One or more stimuli are applied to the person in which each of the one or more stimuli comprises a pseudo random noise component modulating the stimulus intensity. A brain wave signal (4) is detected after applying the one or more stimuli. The detected brain wave signal is processed to calculate which of the one or more stimuli is present in the detected brain wave signal using correlation techniques. The pseudo random noise component comprises a pseudo random noise sequence of the class of maximum length sequences, which are further modulated with twice their associated bit frequency.

公开(公告)号：US10167470B2

公开(公告)日：2019-01-01

申请号：US15963229

申请日：2018-04-26

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Robert Wilhelmus Johanna Collin ,  Franciscus Peter Maria Cremers ,  Antonia Ingrid Den Hollander

IPC: C12N15/113

Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.